LPCAT1-mediated Membrane Phospholipid Remodelling Promotes Ferroptosis Evasion and Tumour Growth
Overview
Authors
Affiliations
The mechanisms underlying the dynamic remodelling of cellular membrane phospholipids to prevent phospholipid peroxidation-induced membrane damage and evade ferroptosis, a non-apoptotic form of cell death driven by iron-dependent lipid peroxidation, remain poorly understood. Here we show that lysophosphatidylcholine acyltransferase 1 (LPCAT1) plays a critical role in ferroptosis resistance by increasing membrane phospholipid saturation via the Lands cycle, thereby reducing membrane levels of polyunsaturated fatty acids, protecting cells from phospholipid peroxidation-induced membrane damage and inhibiting ferroptosis. Furthermore, the enhanced in vivo tumour-forming capability of tumour cells is closely associated with the upregulation of LPCAT1 and emergence of a ferroptosis-resistant state. Combining LPCAT1 inhibition with a ferroptosis inducer synergistically triggers ferroptosis and suppresses tumour growth. Therefore, our results unveil a plausible role for LPCAT1 in evading ferroptosis and suggest it as a promising target for clinical intervention in human cancer.
Li Q, Liu H Int J Mol Sci. 2025; 26(5).
PMID: 40076502 PMC: 11899969. DOI: 10.3390/ijms26051875.
Fei M, Zhang Y, Li H, Xu Q, Gao Y, Yang C Int J Biol Sci. 2025; 21(2):614-631.
PMID: 39781455 PMC: 11705634. DOI: 10.7150/ijbs.103032.
Mechanism of ferroptosis resistance in cancer cells.
Wang Y, Yu G, Chen X Cancer Drug Resist. 2024; 7:47.
PMID: 39624080 PMC: 11609146. DOI: 10.20517/cdr.2024.127.
Ferroptosis: mechanisms and therapeutic targets.
Zhou Q, Meng Y, Le J, Sun Y, Dian Y, Yao L MedComm (2020). 2024; 5(12):e70010.
PMID: 39568772 PMC: 11577302. DOI: 10.1002/mco2.70010.
NFE2L2 and ferroptosis resistance in cancer therapy.
Tang D, Kang R Cancer Drug Resist. 2024; 7:41.
PMID: 39534872 PMC: 11555182. DOI: 10.20517/cdr.2024.123.